Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis
© 2022. The Author(s)..
Leishmaniasis is a neglected protozoan disease affecting over 12 million people globally with no approved vaccines for human use. New World cutaneous leishmaniasis (CL) caused by L. mexicana is characterized by the development of chronic non-healing skin lesions. Using the CRISPR/Cas9 technique, we have generated live attenuated centrin knockout L. mexicana (LmexCen-/-) parasites. Centrin is a cytoskeletal protein important for cellular division in eukaryotes and, in Leishmania, is required only for intracellular amastigote replication. We have investigated the safety and immunogenicity characteristics of LmexCen-/- parasites by evaluating their survival and the cytokine production in bone-marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) in vitro. Our data shows that LmexCen-/- amastigotes present a growth defect, which results in significantly lower parasitic burdens and increased protective cytokine production in infected BMDMs and BMDCs, compared to the wild type (WT) parasites. We have also determined the safety and efficacy of LmexCen-/- in vivo using experimental murine models of L. mexicana. We demonstrate that LmexCen-/- parasites are safe and do not cause lesions in susceptible mouse models. Immunization with LmexCen-/- is also efficacious against challenge with WT L. mexicana parasites in genetically different BALB/c and C57BL/6 mouse models. Vaccinated mice did not develop cutaneous lesions, displayed protective immunity, and showed significantly lower parasitic burdens at the infection site and draining lymph nodes compared to the control group. Overall, we demonstrate that LmexCen-/- parasites are safe and efficacious against New World cutaneous leishmaniasis in pre-clinical models.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
NPJ vaccines - 7(2022), 1 vom: 02. März, Seite 32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Volpedo, Greta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 18.04.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-022-00449-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337681031 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337681031 | ||
| 003 | DE-627 | ||
| 005 | 20231225234952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-022-00449-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337681031 | ||
| 035 | |a (NLM)35236861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Volpedo, Greta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Leishmaniasis is a neglected protozoan disease affecting over 12 million people globally with no approved vaccines for human use. New World cutaneous leishmaniasis (CL) caused by L. mexicana is characterized by the development of chronic non-healing skin lesions. Using the CRISPR/Cas9 technique, we have generated live attenuated centrin knockout L. mexicana (LmexCen-/-) parasites. Centrin is a cytoskeletal protein important for cellular division in eukaryotes and, in Leishmania, is required only for intracellular amastigote replication. We have investigated the safety and immunogenicity characteristics of LmexCen-/- parasites by evaluating their survival and the cytokine production in bone-marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) in vitro. Our data shows that LmexCen-/- amastigotes present a growth defect, which results in significantly lower parasitic burdens and increased protective cytokine production in infected BMDMs and BMDCs, compared to the wild type (WT) parasites. We have also determined the safety and efficacy of LmexCen-/- in vivo using experimental murine models of L. mexicana. We demonstrate that LmexCen-/- parasites are safe and do not cause lesions in susceptible mouse models. Immunization with LmexCen-/- is also efficacious against challenge with WT L. mexicana parasites in genetically different BALB/c and C57BL/6 mouse models. Vaccinated mice did not develop cutaneous lesions, displayed protective immunity, and showed significantly lower parasitic burdens at the infection site and draining lymph nodes compared to the control group. Overall, we demonstrate that LmexCen-/- parasites are safe and efficacious against New World cutaneous leishmaniasis in pre-clinical models | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Pacheco-Fernandez, Thalia |e verfasserin |4 aut | |
| 700 | 1 | |a Holcomb, Erin A |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Lypaczewski, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Blake |e verfasserin |4 aut | |
| 700 | 1 | |a Fultz, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Mishan, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Chaitenya |e verfasserin |4 aut | |
| 700 | 1 | |a Huston, Ryan H |e verfasserin |4 aut | |
| 700 | 1 | |a Wharton, Abigail R |e verfasserin |4 aut | |
| 700 | 1 | |a Dey, Ranadhir |e verfasserin |4 aut | |
| 700 | 1 | |a Karmakar, Subir |e verfasserin |4 aut | |
| 700 | 1 | |a Oghumu, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Hamano, Shinjiro |e verfasserin |4 aut | |
| 700 | 1 | |a Gannavaram, Sreenivas |e verfasserin |4 aut | |
| 700 | 1 | |a Nakhasi, Hira L |e verfasserin |4 aut | |
| 700 | 1 | |a Matlashewski, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Satoskar, Abhay R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 7(2022), 1 vom: 02. März, Seite 32 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:02 |g month:03 |g pages:32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-022-00449-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 02 |c 03 |h 32 | ||